hydralazine has been researched along with Marfan Syndrome in 4 studies
Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.
hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.
Marfan Syndrome: An autosomal dominant disorder of CONNECTIVE TISSUE with abnormal features in the heart, the eye, and the skeleton. Cardiovascular manifestations include MITRAL VALVE PROLAPSE, dilation of the AORTA, and aortic dissection. Other features include lens displacement (ectopia lentis), disproportioned long limbs and enlarged DURA MATER (dural ectasia). Marfan syndrome (type 1) is associated with mutations in the gene encoding FIBRILLIN-1 (FBN1), a major element of extracellular microfibrils of connective tissue. Mutations in the gene encoding TYPE II TGF-BETA RECEPTOR (TGFBR2) are associated with Marfan syndrome type 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Marfan syndrome is an inheritable connective tissue disorder with multisystem involvement and variable expression of signs and symptoms, caused by mutations within the fibrillin gene on chromosome 15q21." | 2.43 | Pregnancy in Marfan syndrome after aortic root replacement: a case report and review of the literature. ( Elami, A; Ezra, Y; Gilon, D; Ginosar, Y; Pollak, A; Volach, V, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Habashi, JP | 2 |
| MacFarlane, EG | 1 |
| Bagirzadeh, R | 1 |
| Bowen, C | 1 |
| Huso, N | 2 |
| Chen, Y | 1 |
| Bedja, D | 2 |
| Creamer, TJ | 1 |
| Rykiel, G | 1 |
| Manning, M | 1 |
| Huso, D | 2 |
| Dietz, HC | 2 |
| Doyle, JJ | 1 |
| Doyle, AJ | 1 |
| Wilson, NK | 1 |
| Whitworth, RE | 1 |
| Lindsay, ME | 1 |
| Schoenhoff, F | 1 |
| Myers, L | 1 |
| Bachir, S | 1 |
| Squires, O | 1 |
| Rusholme, B | 1 |
| Ehsan, H | 1 |
| Thomas, CJ | 1 |
| Caulfield, MJ | 1 |
| Van Eyk, JE | 1 |
| Judge, DP | 1 |
| Volach, V | 1 |
| Elami, A | 1 |
| Gilon, D | 1 |
| Pollak, A | 1 |
| Ginosar, Y | 1 |
| Ezra, Y | 1 |
| Gallop, PM | 1 |
| Paz, MA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions[NCT01322165] | 3,706 participants (Actual) | Observational | 2007-11-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for hydralazine and Marfan Syndrome
| Article | Year |
|---|---|
Pregnancy in Marfan syndrome after aortic root replacement: a case report and review of the literature.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Aortic Diseases; Aortic Dissection; Blo | 2006 |
Posttranslational protein modifications, with special attention to collagen and elastin.
Topics: Amino Acid Sequence; Animals; Antibody Specificity; Ascorbic Acid; Collagen; Connective Tissue; Copp | 1975 |
2 other studies available for hydralazine and Marfan Syndrome
| Article | Year |
|---|---|
Oxytocin antagonism prevents pregnancy-associated aortic dissection in a mouse model of Marfan syndrome.
Topics: Adrenergic beta-Antagonists; Animals; Aorta; Aortic Dissection; Disease Models, Animal; Female; Hydr | 2019 |
A deleterious gene-by-environment interaction imposed by calcium channel blockers in Marfan syndrome.
Topics: Adult; Animals; Antihypertensive Agents; Calcium Channel Blockers; Child; Child, Preschool; Disease | 2015 |